Zinc levels in serum during subcutaneous interleukin-2 immunotherapy of cancer

Dardenne M. , Pleau J.M. , Nabama B. Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci USA 1982; 79: 5370–4.

Mocchegiani E. , Bulian D. , Santarelli L. , Tibaldi A. , Pierpaoli W. , Fabris N. Immuno-enhancing effect of melatonin in old mice may be mediated by zinc turnover. 2nd International Congress of the International Society for Neuroimmunomodulation, p. 204. Paestum, Italy, September 12-17, 1993.

Whittington R. , Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993; 46: 446–514.

Lissoni P. , Barni S. , Archili C. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. Anticancer Res 1990; 10: 753–58.

Viviani S. , Bidoli P. , Spinazzè S. , Rovelli F. , Lissoni P. Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small cell lung cancer patients. J Pineal Res 1992; 12: 114–7.